• 1
    Hirsh J., Anand S., Halperin J., Fuster V. Guide to anticoagulant therapy: Heparin, a statement for healthcare professionals from the American Heart Association. Arterioscler Thromb Vase Biol 2001;21:e9e33.
  • 2
    Hirsh J., Raschke R. Heparin and low molecular weight heparin: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 Suppl):188S203S.
  • 3
    Weitz JI. Drug therapy: Low molecular weight heparins [Review]. New Engl J Med 1997;337:688698.
  • 4
    Levine M., Hirsh J., Gent M., et al. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med 1994;154:4956.
  • 5
    Kakkar V., Howes J., Sharma V., Kadziola Z. A comparative double-blind, randomized trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism: The Bemiparin Assessment group. Thromb Haemost 2000;83:523529.
  • 6
    Farooq V., Hegarty J., Chanddrasekar T., et al. Serious adverse incidents with the usage of low molecular weight heparins in patients with chronic kidney disease. Am J Kid Dis 2004;43:531537.
  • 7
    Chandler W. The thromboelastography and the thromboe-lastograph technique. Sem Thromb Hemost 1995;21(Suppl 4):16.
  • 8
    Klein SM, Slaughter TF, Vail PT, et al. Thromboelastography as a perioperative measure of anticoagulation resulting from low molecular weight heparin: A comparison with anti-Xa concentrations. Anesth Analg 2000;91:10911095.
  • 9
    Zmuda K., Neofotistos D., Tsao C. Effects of unfractionated heparin, low molecular weight heparin, and heparinoid on thromboelastographic assay of blood coagulation. Am J Clin Path 2000;113:725731.
  • 10
    Otto CM, Rieser TM, Brooks MB, Russell MW. Evidence of hypercoagulability in dogs with parvoviral enteritis. J Am Vet Med Assoc 2000;217:15001504.
  • 11
    Donahue SM, Otto CM. Thromboelastography: A tool for measuring hypercoagulability, hypocoagulability, and fibrinolysis. J Vet Emerg Crit Care 2005;15:916.
  • 12
    Grebe S., Jacobs C., Kietzmann M., Mischke R. Pharmacokinetics of the low molecular weight heparin Fragmin D in dogs [in German]. Berl Munch Tierarztl Wochenschr 2000;113:103107.
  • 13
    Mischke R., Grebe S. The correlation between plasma anti-factor Xa activity and haemostatic tests in healthy dogs, after the administration of a low molecular weight heparin. Res Vet Sci 2000;69:241247.
  • 14
    Mischke R., Grebe S., Jacobs C., Kietzmann M. Amidolytic heparin activity and values for several hemostatic variables after repeated subcutaneous administration of high doses of a low molecular weight heparin in healthy dogs. Am J Vet Res 2001;62:595598.
  • 15
    Mischke R., Fehr M., Nolte I. Efficacy of low molecular weight heparin in a canine model of thromboplastin-induced acute disseminated intravascular coagulation. Res Vet Sci 2005;79:6976.
  • 16
    Smith CE, Rozanski EA, Freeman LM, et al. Use of low molecular weight heparin in cats: 57 cases (1999–2003). J Am Vet Med Assoc 2004;225:12371241.
  • 17
    Schwarzwald C., Feige K., Wunderlie-Allenspach H., Braun U. Comparison of pharmacokinetic variables for two low molecular weight heparins after subcutaneous administration of a single dose to horses. Am J Vet Res 2002;63:868873.
  • 18
    Feige K., Schwarzwald C., Bombeli T. Comparison of unfractionated and low molecular weight heparin for prophylaxis of coagulopathies in 52 horses with colic: A randomised double-blind clinical trial. Equine Vet J 2003;35:506513.
  • 19
    Smith S., Tobias A. Feline arterial thromboembolism: An update. Vet Clin Small Animal 2004;34:12451271.
  • 20
    Kittleson MD. Small Animal Cardiovascular Medicine. St. Louis , MO : Mosby; 1998.
  • 21
    Fareed J., Fu K., Yang L., Hoppensteadt D. Pharmacokinetics of low molecular weight heparins in animal models. Sem Thromb Hemost 1999;25(Suppl 3):5155.
  • 22
    Brooks MB. Evaluation of a chromogenic assay to measure the factor Xa inhibitory activity of unfractionated heparin in canine plasma. Vet Clin Path 2004;33:208214.
  • 23
    Greene C., Meriwether E. Activated partial thromboplastin time and activated coagulation time in monitoring heparinized cats. Am J Vet Res 1982;43:14731477.
  • 24
    Ritschel WA. Handbook of Basic Pharmacokinetics: Including Clinical Applications, 3rd ed. Hamilton , IL : Drug Intelligence Publications; 1986.
  • 25
    Winter ME. Basic Clinical Pharmacokinetics, 4th ed. Philadelphia , PA : Lippincott Williams & Wilkins; 2004.
  • 26
    Montalescot G., Collet J., Tanguy M., et al. Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin. Circulation 2004;110:392398.
  • 27
    Collignon F., Frydman A., Caplain H., et al. Comparison of pharmacokinetic profiles of three low molecular mass heparins: Dalteparin, enoxaparin, and nardoparin—administered subcuta-neously in healthy volunteers. Thromb Haemost 1995;73:630640.
  • 28
    Boneu B. Low molecular weight heparin therapy: Is monitoring needed Thromb Haemost 1994;72:330334.
  • 29
    Fareed J., Jeske W., Hoppensteadt D., et al. Low molecular weight heparins: Pharmacologic profile and product differentiation. Amer J Cardiol 1998;82:3L10L.
  • 30
    Fraser GL, McKenna JP. Monitoring low molecular weight heparins with anti-Xa activity: House of cards or firm foundation Hosp Pharm 2003;38:202211.
  • 31
    Hoppensteadt D., Walenga J., Fareed J., et al. Heparin, low molecular weight heparins, and heparin pentasaccharide: Basic and clinical differentiation. Hematol Onco Clin North Am 2003;17:313341.
  • 32
    Laposta M., Green D., Van Cott E., et al. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy. Arch Pathol Lab Med 1998;122:799807.
  • 33
    Yee JYV, Duffull SB. The effect of body weight on dalteparin pharmacokinetics. Eur J Clin Pharmacol 2000;56:293297.
  • 34
    Al Died R., Wagenvoord R., VanDedem G., et al. The inhibition of blood coagulation by heparins of different molecular weight is caused by a common functional motif: The C-domain. J Thromb Haemost 2003;1:907914.
  • 35
    Levi M. All heparins are equal but some are more equal. J Thromb Haemost 2003;1:884885.
  • 36
    Melissari E., Parker C., Wilson N., et al. Use of low molecular weight heparin in pregnancy. Thromb Haemostasis 1992;68:652656.